{"schemaVersion":"ready-scan.resource-sources.v1","locale":"en","path":"/sources/source-f76c27ae50ea232c","canonicalUrl":"https://readyscan.ai/sources/source-f76c27ae50ea232c","machineUrl":"https://readyscan.ai/discovery/sources/source-f76c27ae50ea232c.json","page":1,"pageSize":48,"totalCount":1,"totalPages":1,"previous":null,"next":null,"kind":"source","source":{"id":"source-f76c27ae50ea232c","url":"https://catalystexplains.com/faq/","title":"Catalyst: /faq/","publisher":"catalystexplains.com","publicationCount":1,"modifiedOn":"2026-10-24","path":"/sources/source-f76c27ae50ea232c","canonicalUrl":"https://readyscan.ai/sources/source-f76c27ae50ea232c","machineUrl":"https://readyscan.ai/discovery/sources/source-f76c27ae50ea232c.json"},"items":[{"key":"subject:Q139885826","citations":[{"id":"source-f76c27ae50ea232c","url":"https://catalystexplains.com/faq/","title":"Catalyst: /faq/","publisher":"catalystexplains.com","accessedOn":"2026-10-24"}],"editions":[{"language":"en","title":"Catalyst","description":"Houston-based U.S. company combining GLP-class peptide commerce with science-explainer publishing on peptide therapeutics.","path":"/entities/catalyst-q139885826","canonicalUrl":"https://readyscan.ai/entities/catalyst-q139885826","machineUrl":"https://readyscan.ai/discovery/entities/catalyst-q139885826.json","modifiedOn":"2026-10-24"}],"subject":{"slug":"catalyst-q139885826","name":"Catalyst","questions":[{"question":"What does “third generation” mean?","path":"/entities/catalyst-q139885826#company-answer-content-native-digital-agencies-bd8118dce10aa767-a-3c33d96996b850d01828"},{"question":"Why do newer GLP compounds target more than one receptor?","path":"/entities/catalyst-q139885826#company-answer-content-native-digital-agencies-bd8118dce10aa767-a-7546100b22fa65a8c1ef"},{"question":"Where can I go deeper?","path":"/entities/catalyst-q139885826#company-answer-content-native-digital-agencies-bd8118dce10aa767-a-1879eadd9be98c9d7c02"},{"question":"What is changing in the GLP market?","path":"/entities/catalyst-q139885826#company-answer-content-native-digital-agencies-bd8118dce10aa767-a-5a9e31bda2357834115b"},{"question":"Where can I follow new GLP developments?","path":"/entities/catalyst-q139885826#company-answer-content-native-digital-agencies-bd8118dce10aa767-a-6daeda7912fea6157cbd"}],"facts":[{"id":"content-native-digital-agencies-bd8118dce10aa767-a-3c33d96996b850d01828","label":"What does “third generation” mean?","value":"“In Catalyst's GLP-3 coverage, third generation describes research built around three receptor pathways: GLP-1, GIP, and glucagon.”","path":"/entities/catalyst-q139885826#company-fact-content-native-digital-agencies-bd8118dce10aa767-a-3c33d96996b850d01828","questionPaths":["/entities/catalyst-q139885826#company-answer-content-native-digital-agencies-bd8118dce10aa767-a-3c33d96996b850d01828"]},{"id":"content-native-digital-agencies-bd8118dce10aa767-a-7546100b22fa65a8c1ef","label":"Why do newer GLP compounds target more than one receptor?","value":"“Researchers are studying whether combining complementary metabolic signals can produce broader effects than targeting a single pathway alone.”","path":"/entities/catalyst-q139885826#company-fact-content-native-digital-agencies-bd8118dce10aa767-a-7546100b22fa65a8c1ef","questionPaths":["/entities/catalyst-q139885826#company-answer-content-native-digital-agencies-bd8118dce10aa767-a-7546100b22fa65a8c1ef"]},{"id":"content-native-digital-agencies-bd8118dce10aa767-a-1879eadd9be98c9d7c02","label":"Where can I go deeper?","value":"“Science Explained articles connect related guides and cited sources so readers can move from a plain-language introduction into the underlying research.”","path":"/entities/catalyst-q139885826#company-fact-content-native-digital-agencies-bd8118dce10aa767-a-1879eadd9be98c9d7c02","questionPaths":["/entities/catalyst-q139885826#company-answer-content-native-digital-agencies-bd8118dce10aa767-a-1879eadd9be98c9d7c02"]},{"id":"content-native-digital-agencies-bd8118dce10aa767-a-5a9e31bda2357834115b","label":"What is changing in the GLP market?","value":"“The category is moving from single-receptor medicines toward dual- and triple-receptor research, while new delivery formats, indications, and access models continue to develop.”","path":"/entities/catalyst-q139885826#company-fact-content-native-digital-agencies-bd8118dce10aa767-a-5a9e31bda2357834115b","questionPaths":["/entities/catalyst-q139885826#company-answer-content-native-digital-agencies-bd8118dce10aa767-a-5a9e31bda2357834115b"]},{"id":"content-native-digital-agencies-bd8118dce10aa767-a-6daeda7912fea6157cbd","label":"Where can I follow new GLP developments?","value":"“Peptide News covers current developments, while Science Explained provides the deeper background needed to understand why they matter.”","path":"/entities/catalyst-q139885826#company-fact-content-native-digital-agencies-bd8118dce10aa767-a-6daeda7912fea6157cbd","questionPaths":["/entities/catalyst-q139885826#company-answer-content-native-digital-agencies-bd8118dce10aa767-a-6daeda7912fea6157cbd"]}]},"selected":{"language":"en","title":"Catalyst","description":"Houston-based U.S. company combining GLP-class peptide commerce with science-explainer publishing on peptide therapeutics.","path":"/entities/catalyst-q139885826","canonicalUrl":"https://readyscan.ai/entities/catalyst-q139885826","machineUrl":"https://readyscan.ai/discovery/entities/catalyst-q139885826.json","modifiedOn":"2026-10-24"}}],"versionId":"fnv1a64:8e5e42f201c6bdc3"}